

ACUMEN PHARMACEUTICALS NAMES DR. WILLIAM F. GOURE PRESIDENT AND CHIEF EXECUTIVE OFFICER

SOUTH SAN FRANCISCO, Calif., May 16, 2008 – Acumen Pharmaceuticals, a pre-clinical biotech company focusing on treatments for Alzheimer's disease, today announced that it has promoted Dr. **William F. Goure** to the post of President and Chief Executive Officer (CEO). A veteran of more than 22 years in the discovery, development, registration, and commercialization of chemical and biotechnology products, Dr. Goure formerly served as Chief Operating Officer at the company.

In his new role, Dr. Goure will be responsible for leading the company's reorganization to a virtual company and directing and coordinating activities with consultants, advisors, and R&D partners to ensure achievement of the company's business, financial, and R&D goals.

"As the company's technology matured and our business model evolved we recognized that Dr. Goure's leadership skills and broad based business and technical expertise were ideally suited for leading the company into its next phase" said Dr. Grant Krafft, Chairman and Co-Founder at Acumen. "His leadership and organizational skills, high standards and focus on execution continue to be real assets to our organization."

Prior to joining Acumen in 2004, Dr. Goure was Vice President for Commercial Development for Mendel Biotechnology, a San Francisco Bay area company working on the discovery, development and commercialization of genetically enhanced agricultural and plant products. At Mendel, Dr. Goure negotiated numerous technology collaboration and partnership agreements that generated more than \$29 million dollars of near-term revenues. Dr. Goure also worked at Monsanto Company for 17 years with positions in discovery, product development, environmental sciences, and business development. Dr. Goure was a member of teams that developed and commercialized Roundup Ready® soybeans, canola, corn, cotton, and sugar beets.

Dr. Goure has a B.S. degree in chemistry from Fort Lewis College in Durango, Colorado and a Ph.D. degree in organic chemistry from Iowa State University. Prior to joining Monsanto, he was a Post-Doctoral Fellow at Colorado State University.

About Acumen

Acumen Pharmaceuticals is a discovery stage biotechnology company focused on discovering and developing in partnership with leading pharmaceutical companies best in class therapeutics and diagnostics for Alzheimer's disease. Acumen owns or has exclusive license to a broad set of patents, related intellectual property and drug development capabilities relating to amyloid beta soluble oligomers, now widely believed to be an underlying cause of Alzheimer's disease. Acumen is partnered with Merck & Co. for the development of certain monoclonal antibody therapeutics. NeuroVentures LLC and Biotechnology Value Fund LP have made investments in the company.